Increased fatty acyl saturation of phosphatidylinositol phosphates in prostate cancer progression.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
13 09 2019
Historique:
received: 12 04 2019
accepted: 30 08 2019
entrez: 15 9 2019
pubmed: 15 9 2019
medline: 31 10 2020
Statut: epublish

Résumé

Phosphoinositides (PIPs) participate in many cellular processes, including cancer progression; however, the metabolic features of PIPs associated with prostate cancer (PCa) are unknown. We investigated PIPs profiles in PTEN-deficient prostate cancer cell lines, human prostate tissues obtained from patients with PCa and benign prostate hyperplasia (BPH) specimens using mass spectrometry. In immortalized normal human prostate PNT1B cells, PTEN deficiency increased phosphatidylinositol tris-phosphate (PIP

Identifiants

pubmed: 31520002
doi: 10.1038/s41598-019-49744-3
pii: 10.1038/s41598-019-49744-3
pmc: PMC6744559
doi:

Substances chimiques

Phosphatidylinositol Phosphates 0
PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13257

Références

Neoplasia. 2004 Nov-Dec;6(6):846-53
pubmed: 15720812
Nature. 2010 May 27;465(7297):497-501
pubmed: 20463662
Carcinogenesis. 2016 Dec;37(12):1129-1137
pubmed: 27915273
Int J Mol Med. 2003 Aug;12(2):253-7
pubmed: 12851727
J Physiol. 2010 Sep 1;588(Pt 17):3179-85
pubmed: 20519312
Prog Lipid Res. 2009 Nov;48(6):307-43
pubmed: 19580826
Sci Rep. 2014 Aug 05;4:5959
pubmed: 25091112
Cancer Metab. 2016 Apr 01;4:6
pubmed: 27042297
Nat Rev Cancer. 2007 Oct;7(10):763-77
pubmed: 17882277
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Mol Cancer Ther. 2010 Jun;9(6):1740-54
pubmed: 20530718
Biochim Biophys Acta. 2013 Oct;1831(10):1518-32
pubmed: 23562839
Cancer Discov. 2015 Jul;5(7):730-9
pubmed: 25883023
Cancer Res. 2010 Oct 15;70(20):8117-26
pubmed: 20876798
Cancer Discov. 2018 Jun;8(6):764-779
pubmed: 29581176
Arch Med Res. 2017 Jan;48(1):46-54
pubmed: 28577869
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cell Rep. 2015 Jan 6;10(1):8-19
pubmed: 25543136
Prostate. 2015 Dec;75(16):1821-30
pubmed: 26332786
Nat Methods. 2011 Mar;8(3):267-72
pubmed: 21278744
Cancer Res. 2011 May 1;71(9):3236-45
pubmed: 21415164
Oncogenesis. 2016 Feb 15;5:e195
pubmed: 26878389
Cancer Cell. 2003 Sep;4(3):209-21
pubmed: 14522255
Cancer Res. 2011 Jan 15;71(2):572-82
pubmed: 21224358
Oncotarget. 2014 May 30;5(10):3273-86
pubmed: 24830350
J Chromatogr A. 2013 Apr 26;1287:84-95
pubmed: 23332303
PLoS One. 2014 Feb 28;9(2):e90242
pubmed: 24587297

Auteurs

Atsushi Koizumi (A)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan.

Shintaro Narita (S)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. nari6202@gipc.akita-u.ac.jp.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan. nari6202@gipc.akita-u.ac.jp.

Hiroki Nakanishi (H)

Research Center for Biosignaling, Akita University, Akita, Japan.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan.

Masaki Ishikawa (M)

Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan.

Satoshi Eguchi (S)

Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan.

Hirotaka Kimura (H)

Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan.

Shunsuke Takasuga (S)

Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan.

Mingguo Huang (M)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan.

Takamitsu Inoue (T)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan.

Junko Sasaki (J)

Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan.
Department of Biochemical Pathophysiology/Lipid Biology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan.

Toshiaki Yoshioka (T)

Department of Occupational Therapy, Akita University Graduate School of Health Science, Akita, Japan.

Tomonori Habuchi (T)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan.

Takehiko Sasaki (T)

Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan.
Department of Biochemical Pathophysiology/Lipid Biology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
AMED-CREST, Japan Agency for Medical Research and Development, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH